Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Neoplasms 49Lymphoma 30Lung Neoplasms 29Breast Neoplasms 28Prostatic Neoplasms 25Multiple Myeloma 25Melanoma 21Lymphoma, Non-Hodgkin 20Carcinoma, Non-Small-Cell Lung 20Ovarian Neoplasms 19Leukemia, Myeloid, Acute 19Glioma 18Pancreatic Neoplasms 17Neoplasm Metastasis 17Urinary Bladder Neoplasms 15Hematologic Neoplasms 15Colorectal Neoplasms 14Carcinoma, Renal Cell 14Burkitt Lymphoma 14Sarcoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Neuroblastoma 13Colonic Neoplasms 12Carcinoma 12Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Myelodysplastic Syndromes 11Leukemia, Lymphocytic, Chronic, B-Cell 11Ependymoma 11Brain Neoplasms 11

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Fallopian Tube Mucinous Adenocarcinoma × 30 days × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡